Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08SOF
|
|||
| Former ID |
DAP000102
|
|||
| Drug Name |
Terfenadine
|
|||
| Synonyms |
Aldaban; Allerplus; Cyater; Hisfedin; Rapidal; Seldane; Teldane; Teldanex; Terdin; Terfedura; Terfemundin; Terfen; Terfenadina; Terfenadinum; Terfenidine; Terfex; Ternadin; Triludan; Aliud Brand of Terfenadine; Balkis Saft Spezial; Bial Brand of Terfenadine; Cantabria Brand of Terfenadine; Ct Arzneimittel Brand of Terfenadine; Dolorgiet Brand of Terfenadine; Heumann Brand of Terfenadine; Hoechst Brand of Terfenadine; Merck dura Brand of Terfenadine; Mundipharma Brand of Terfenadine; Ratiopharm Brand of Terfenadine; Sigma Tau Brand of Terfenadine; Stadapharm Brand of Terfenadine; Terfenadin AL; Terfenadin Heumann; Terfenadin Stada; Terfenadin von ct; Wolff Brand of Terfenadine; MDL 9918; RMI 9918; RMI9918; T 9652; Ct-Arzneimittel Brand of Terfenadine; MDL-9918; RMI-9918; Seldane (TN); Sigma-Tau Brand of Terfenadine; Teldane (TN); Terfenadin-ratiopharm; Terfenadina [INN-Spanish]; Terfenadinum [INN-Latin]; Triludan (TN); Terfenadine (JAN/USAN/INN); Terfenadine [USAN:BAN:INN:JAN]; Alpha-(4-[1,1-Dimethylethyl]phenyl)-4-[hydroxydiphenylmethyl]-1-piperidinebutanol; Alpha-(p-tert-Butylphenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; Alpha-[4-(1,1-Dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; Alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperdinebutanol; Alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperidinebutanol; Alpha-(4-(1,1-dimethylethyl)phenyl)-4-(hydroxydiphenyl-methyl)-1-piperidine butanol; 1-(4-tert-Butylphenyl)-4-(4-(alpha-hydroxybenzhydryl)piperidino)-butan-1-ol; 1-(4-tert-butylphenyl)-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butan-1-ol; 1-(4-tert-butylphenyl)-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butan-1-ol; 1-(p-tert-Butylphenyl)-4-(4'-(alpha-hydroxydiphenylmethyl)-1'-piperidyl)butanol; 1-[4-(1,1-dimethylethyl)phenyl]-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butan-1-ol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Allergy [ICD-11: 4A80-4A85; ICD-10: T78.4; ICD-9: 995.3] | Withdrawn from market | [1], [2] | |
| Therapeutic Class |
Antihistamines
|
|||
| Company |
Marion Merrell. Dow, Inc.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C32H41NO2
|
|||
| Canonical SMILES |
CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O
|
|||
| InChI |
1S/C32H41NO2/c1-31(2,3)26-18-16-25(17-19-26)30(34)15-10-22-33-23-20-29(21-24-33)32(35,27-11-6-4-7-12-27)28-13-8-5-9-14-28/h4-9,11-14,16-19,29-30,34-35H,10,15,20-24H2,1-3H3
|
|||
| InChIKey |
GUGOEEXESWIERI-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 50679-08-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9666, 511394, 855647, 3154381, 5639782, 7847587, 7980761, 8150039, 8153324, 10321465, 10524514, 11336186, 11361425, 11427139, 11462397, 11466166, 11467286, 11485891, 12013836, 14907543, 17405767, 24277779, 26752308, 29224457, 46507007, 47662382, 47662383, 47736580, 47810839, 47810840, 48035221, 48110535, 48416601, 49698808, 49703451, 50015354, 50105228, 50105229, 53778319, 53787217, 56422373, 57322760, 79821290, 85089724, 85209594, 85231279, 85787897, 90341346, 92125182, 92303330
|
|||
| ChEBI ID |
CHEBI:9453
|
|||
| SuperDrug ATC ID |
R06AX12
|
|||
| SuperDrug CAS ID |
cas=050679088
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides uniformis
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides uniformis was decreased by Terfenadine (adjusted p-values: 1.69E-03). | |||
|
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides vulgatus was decreased by Terfenadine (adjusted p-values: 1.56E-03). | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Odoribacter splanchnicus was decreased by Terfenadine (adjusted p-values: 2.11E-03). | |||
|
Studied Microbe: Parabacteroides distasonis
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides distasonis was decreased by Terfenadine (adjusted p-values: 4.86E-04). | |||
|
Studied Microbe: Parabacteroides merdae
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides merdae was decreased by Terfenadine (adjusted p-values: 9.71E-04). | |||
|
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Prevotella copri was decreased by Terfenadine (adjusted p-values: 9.10E-05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium longum
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bifidobacterium longum was decreased by Terfenadine (adjusted p-values: 3.13E-05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
|
Studied Microbe: Collinsella aerofaciens
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Collinsella aerofaciens was decreased by Terfenadine (adjusted p-values: 1.40E-03). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Clostridioides difficile
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Clostridioides difficile was decreased by Terfenadine (adjusted p-values: 7.39E-03). | |||
|
Studied Microbe: Clostridium perfringens
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Clostridium perfringens was decreased by Terfenadine (adjusted p-values: 8.99E-03). | |||
|
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Coprococcus comes was decreased by Terfenadine (adjusted p-values: 5.24E-04). | |||
|
Studied Microbe: Dorea formicigenerans
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Dorea formicigenerans was decreased by Terfenadine (adjusted p-values: 4.50E-03). | |||
|
Studied Microbe: Eubacterium eligens
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium eligens was decreased by Terfenadine (adjusted p-values: 5.76E-04). | |||
|
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium rectale was decreased by Terfenadine (adjusted p-values: 1.59E-03). | |||
|
Studied Microbe: Roseburia hominis
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia hominis was decreased by Terfenadine (adjusted p-values: 3.74E-05). | |||
|
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia intestinalis was decreased by Terfenadine (adjusted p-values: 1.33E-04). | |||
|
Studied Microbe: Ruminococcus gnavus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus gnavus was decreased by Terfenadine (adjusted p-values: 7.41E-04). | |||
|
Studied Microbe: Ruminococcus torques
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus torques was decreased by Terfenadine (adjusted p-values: 1.18E-04). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Veillonellales | ||||
|
Studied Microbe: Veillonella parvula
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Veillonella parvula was decreased by Terfenadine (adjusted p-values: 2.97E-03). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H1 receptor (H1R) | Target Info | Antagonist | [4], [5] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | Histamine H1 receptor mediated signaling pathway | |||
| Reactome | Histamine receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| IL-4 Signaling Pathway | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2608). | |||
| REF 2 | Comparative tolerability of second generation antihistamines. Drug Saf. 1999 May;20(5):385-401. | |||
| REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 4 | Small mouse cholangiocytes proliferate in response to H1 histamine receptor stimulation by activation of the IP3/CaMK I/CREB pathway. Am J Physiol Cell Physiol. 2008 Aug;295(2):C499-513. | |||
| REF 5 | Second-generation antihistamines: a comparative review. Drugs. 1999 Jan;57(1):31-47. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.